BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21113139)

  • 1. Fibrolamellar carcinomas are positive for CD68.
    Ross HM; Daniel HD; Vivekanandan P; Kannangai R; Yeh MM; Wu TT; Makhlouf HR; Torbenson M
    Mod Pathol; 2011 Mar; 24(3):390-5. PubMed ID: 21113139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholangiocarcinomas arising in cirrhosis and combined hepatocellular-cholangiocellular carcinomas share apomucin profiles.
    Sasaki M; Nakanuma Y; Ho SB; Kim YS
    Am J Clin Pathol; 1998 Mar; 109(3):302-8. PubMed ID: 9495202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrolamellar carcinoma versus scirrhous hepatocellular carcinoma : diagnostic usefulness of CD68.
    Limaiem F; Bouraoui S; Sboui M; Bouslama S; Lahmar A; Mzabi S
    Acta Gastroenterol Belg; 2015 Dec; 78(4):393-8. PubMed ID: 26712049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
    Schoedel KE; Tyner VZ; Kim TH; Michalopoulos GK; Mars WM
    Mod Pathol; 2003 Jan; 16(1):14-21. PubMed ID: 12527708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tricellulin expression and its prognostic significance in primary liver carcinomas.
    Somorácz A; Korompay A; Törzsök P; Patonai A; Erdélyi-Belle B; Lotz G; Schaff Z; Kiss A
    Pathol Oncol Res; 2014 Oct; 20(4):755-64. PubMed ID: 24652413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Claudins and tricellulin in fibrolamellar hepatocellular carcinoma.
    Patonai A; Erdélyi-Belle B; Korompay A; Somorácz A; Straub BK; Schirmacher P; Kovalszky I; Lotz G; Kiss A; Schaff Z
    Virchows Arch; 2011 Jun; 458(6):679-88. PubMed ID: 21503766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleolar organizer regions in cirrhosis and hepatocellular carcinoma.
    Jain R; Malhotra V; Kumar N; Sarin SK
    Trop Gastroenterol; 1998; 19(3):100-1. PubMed ID: 9828706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytologic features of fibrolamellar carcinoma with mucin production: a rare variant of combined hepatocellular-cholangiocarcinoma.
    Rosa M; Mohammadi A
    Diagn Cytopathol; 2014 May; 42(5):431-5. PubMed ID: 23008149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of the anterior gradient protein-2 is a conserved feature during morphogenesis and carcinogenesis of the biliary tree.
    Lepreux S; Bioulac-Sage P; Chevet E
    Liver Int; 2011 Mar; 31(3):322-8. PubMed ID: 21281432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined hepatocellular carcinoma and cholangiocarcinoma with components of mucinous carcinoma arising in a cirrhotic liver.
    Morita D; Kagata Y; Ogata S; Tsuda H; Hatsuse K; Mochizuki H; Matsubara O
    Pathol Int; 2006 Apr; 56(4):222-6. PubMed ID: 16634969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical and molecular features of cholangiolocellular carcinoma are similar to well-differentiated intrahepatic cholangiocarcinoma.
    Balitzer D; Joseph NM; Ferrell L; Shafizadeh N; Jain D; Zhang X; Yeh M; di Tommaso L; Kakar S
    Mod Pathol; 2019 Oct; 32(10):1486-1494. PubMed ID: 31186529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bile salt export pump: a sensitive and specific immunohistochemical marker of hepatocellular carcinoma.
    Lagana SM; Salomao M; Remotti HE; Knisely AS; Moreira RK
    Histopathology; 2015 Mar; 66(4):598-602. PubMed ID: 25378077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.
    Akiba J; Nakashima O; Hattori S; Tanikawa K; Takenaka M; Nakayama M; Kondo R; Nomura Y; Koura K; Ueda K; Sanada S; Naito Y; Yamaguchi R; Yano H
    Am J Surg Pathol; 2013 Apr; 37(4):496-505. PubMed ID: 23388123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum.
    Shafizadeh N; Ferrell LD; Kakar S
    Mod Pathol; 2008 Aug; 21(8):1011-8. PubMed ID: 18536657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic significance of combined hepatocellular-cholangiocarcinoma with stem cell subtype components with reference to the expression of putative stem cell markers.
    Ikeda H; Harada K; Sato Y; Sasaki M; Yoneda N; Kitamura S; Sudo Y; Ooi A; Nakanuma Y
    Am J Clin Pathol; 2013 Sep; 140(3):329-40. PubMed ID: 23955451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mixed hepatocellular-cholangiocarcinoma may derive from "hepatogones".
    Hunt JP; Varnholt H
    Hepatobiliary Pancreat Dis Int; 2008 Feb; 7(1):105; author reply 105-6. PubMed ID: 18234649
    [No Abstract]   [Full Text] [Related]  

  • 17. Anterior gradient-2 is overexpressed by fibrolamellar carcinomas.
    Vivekanandan P; Micchelli ST; Torbenson M
    Hum Pathol; 2009 Mar; 40(3):293-9. PubMed ID: 18973922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative lengthening of telomeres in primary hepatic neoplasms.
    Yasir S; Thompson S; Chen ZE; Knudson R; Knutson D; Kloft-Nelson S; Graham RP; Jain D; Simon SM; Wu TT; Torbenson M
    Hum Pathol; 2023 Jan; 131():79-86. PubMed ID: 36370823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation.
    Ward SC; Huang J; Tickoo SK; Thung SN; Ladanyi M; Klimstra DS
    Mod Pathol; 2010 Sep; 23(9):1180-90. PubMed ID: 20495535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
    Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
    J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.